1.A Study on the Methylation of p 16 Gene Promotor in the Uterine Cervical Neoplasia.
Dong Han BAE ; Min Kwan KIM ; Chung Il LEE ; Chang Jin KIM
Korean Journal of Obstetrics and Gynecology 2000;43(9):1525-1532
No abstract available.
Methylation*
2.CpG island methylation and gynecolgic malignancy.
Yong Tark JEON ; Jae Weon KIM ; Soon Beom KANG
Korean Journal of Gynecologic Oncology 2005;16(1):1-7
No abstract available.
CpG Islands*
;
Methylation*
3.Protein Methylation and Interaction with the Antiproliferative Gene, BTG2(/TIS21/Pc3).
Woon Ki PAIK ; Sangduk KIM ; In Kyoung LIM
Yonsei Medical Journal 2014;55(2):292-303
The last one and half a decade witnessed an outstanding re-emergence of attention and remarkable progress in the field of protein methylation. In the present article, we describe the early discoveries in research and review the role protein methylation played in the biological function of the antiproliferative gene, BTG2(/TIS21/PC3).
Methylation*
;
Protein Methyltransferases
4.Advance of study on demethylation in leukemia - review.
Bei-Ming SHOU ; Bao-An CHEN ; De-Long LIU
Journal of Experimental Hematology 2008;16(5):1247-1250
DNA methylation is a frequent change in epigenetics of leukemia. In the development of leukemia, methylation plays an important role in the genetic expression regulation and genetic structure stabilization. Hematopoietic stem cell transplantation (HSCT) and chemotherapy are the common methods to cure leukemia at present. Unfortunately, it is very hard to find suitable donor for transplantation, while the relapse and drug resistance are the unresolved problems in chemotherapy. Because of the reversibility of methylation, the drugs reducing the level of methylation become a new way to cure leukemia. Decitabine is the most common medicament used to reduce the level of methylation. In this article, the methylation and tumor, methylation and hematologic diseases, methylation detection methods, demethylation therapy in leukemia and so on are reviewed.
DNA Methylation
;
Humans
;
Leukemia
5.Lack of methylation changes in GJB2 and RB1 non-coding regions of cochlear implant patients with sensorineural hearing loss
Angelo Augusto M. Sumalde ; Ivana V. Yang ; Talitha Karisse L. Yarza ; Celina Ann M. Tobias-Grasso ; Ma. Leah C. Tantoco ; Elizabeth Davidson ; Abner L. Chan ; Mahshid S. Azamian ; Teresa Luisa G. Cruz ; Seema R. Lalani ; Maria Rina T. Reyes-Quintos ; Eva Maria Cutiongco-de la Paz ; Regie Lyn P. Santos-Cortez ; Charlotte M. Chiong
Acta Medica Philippina 2023;57(9):116-120
Objective:
Recent advances in epigenetic studies continue to reveal novel mechanisms of gene regulation and control, however little is known on the role of epigenetics in sensorineural hearing loss (SNHL) in humans. We aimed to investigate the methylation patterns of two regions, one in RB1 and another in GJB2 in Filipino patients with SNHL compared to hearing control individuals.
Methods:
We investigated an RB1 promoter region that was previously identified as differentially methylated in children with SNHL and lead exposure. Additionally, we investigated a sequence in an enhancer-like region within GJB2 that contains four CpGs in close proximity. Bisulfite conversion was performed on salivary DNA samples from 15 children with SNHL and 45 unrelated ethnically-matched individuals. We then performed methylation-specific real-time PCR analysis (qMSP) using TaqMan® probes to determine percentage methylation of the two regions.
Results:
Using qMSP, both our cases and controls had zero methylation at the targeted GJB2 and RB1 regions.
Conclusion
Our study showed no changes in methylation at the selected CpG regions in RB1 and GJB2 in the two comparison groups with or without SNHL. This may be due to a lack of environmental exposures to these target regions. Other epigenetic marks may be present around these regions as well as those of other HL-associated genes.
Hearing Loss
;
Methylation
6.Advances of research on demethylation therapy for hematologic malignancies.
Journal of Experimental Hematology 2009;17(5):1394-1398
DNA methylation is an important and reversible epigenetic modification which regulates genomic stability. Methylation is essential for mammalian development. Generally, gene expression level and DNA methylation are negative correlation. Transcriptional silencing via methylation of CpG islands in the promoter is important for cell growth and differentiation and plays a key role in tumorigenesis. Demethylation drug can modify chromatin and restore the ability of anti-oncogene. Demethylation therapy as a new therapy may treat efficiently hematological malignancies with resistance and relapse. In this review, DNA methylation mechanism, relationship between aberrant methylation and hematologic malignancies, mechanism of demethylation therapy, the advance of research on the demethylation therapy of hematological malignancies, such as acute and chronic leukemia, lymphoma, myelodysplastic syndrome were summarized.
DNA Methylation
;
Hematologic Neoplasms
;
genetics
;
metabolism
;
therapy
;
Humans
;
Methylation
7.Current situation researching of methylation in tumor.
Di SHAO ; An-fang CUI ; Liu-luan ZHU ; Ai-jun QIAO ; Xing-xing KONG ; Xiao-jun LIU ; Yong-sheng CHANG ; Fu-de FANG
Acta Academiae Medicinae Sinicae 2009;31(6):786-790
The disorders of DNA and histone methylation have a close relationship with the development and progression of tumors. Epigenetic regulation is critical in maintaining the stability and integrity of the expression profiles of different cell types by modifying DNA methylation and histone methylation. However, the abnormal changes of methylation often result in the development and progression of tumors. This review summarized the theory of tumor genomic and histone methylation, detection methods of methylation and their applications, and the clinical application of methylation as biological markers and drug targets.
DNA Methylation
;
Histones
;
metabolism
;
Humans
;
Methylation
;
Neoplasms
;
genetics
;
metabolism
8.Methylation and demethylation of DNA and histones in chromatin: the most complicated epigenetic marker.
Experimental & Molecular Medicine 2017;49(4):e321-
No abstract available.
Chromatin*
;
DNA*
;
Epigenomics*
;
Histones*
;
Methylation*
9.Syndecan-2 Methylation as a New Biomarker for Early Detection of Colorectal Neoplasm.
Gut and Liver 2018;12(5):479-480
No abstract available.
Colorectal Neoplasms*
;
Methylation*
;
Syndecan-2*
10.Application of methyltransferases in microbial synthesis of natural products.
Xiangyan ZHANG ; Xiaolin SHEN ; Xinxiao SUN ; Jia WANG ; Qipeng YUAN
Chinese Journal of Biotechnology 2021;37(6):1869-1886
Methyltransferases (MTs) constitute a large group of enzymes that catalyze the transfer of a methyl moiety, most frequently from S-adenosyl-L-methionine, to their substrates. It plays an essential role in regulation of gene expression and synthesis of many natural compounds. Owing to its broad substrate spectrum, MTs make important contributions to diversify the spectrum of products through methylation modifications. Recently, great progress has been made in application of MTs for the biosynthesis of various natural products including phenylpropane compounds, fragrances, hormones and antibiotics, which is summarized in this review. Moreover, we highlighted the strategies of using MTs for efficient production and for expanding the diversity of these methylated natural products, and discussed the current challenges and future prospects in this area.
Biological Products
;
Methylation
;
Methyltransferases/metabolism*